Industry1h ago
Industry
Nanyang Biologics Advances Toward Nasdaq Listing
Shareholders approved the RFAI vote for Nanyang Biologics, clearing a path for its Nasdaq listing. The9 expects to hold a 15% to 16% stake in the combined entity. This move funds the company's AI-driven drug discovery pipeline. Investors now watch for the final listing date to gauge the market value of these AI biotech assets.